INFORMATION FOR HEALTHCARE PROFESSIONALS
Safety InformationSign Up | E-mail a Colleague

About ULORIC

ULORIC powerfully lowers serum uric acid to target levels of < 6 mg/dL

Treating hyperuricemia is the key to long-term management of chronic gout. A sustained serum uric acid level of < 6 mg/dL is the goal of anti-hyperuricemic therapy and has been established as appropriate for the treatment of gout.

ULORIC was studied in controlled trials of 6 months and 1 year, and in open-label extension trials for up to 5 years.

In the largest Phase 3 Study (6 months):

  • 45% of patients who received ULORIC 40 mg achieved a serum uric acid level of < 6 mg/dL at final visit (N=757) compared to 42% of patients who received allopurinol 300 mg (N=755; p=0.233).
  • 67% of patients who received ULORIC 80 mg achieved a serum uric acid level of < 6 mg/dL at final visit (N=756) compared to 42% of patients who received allopurinol 300 mg (N=755; p<0.001).

More than 2 times as many patients with a baseline serum uric acid of ≥ 10 mg/dL achieved a serum uric acid level of < 6 mg/dL with ULORIC 80 mg.

83% of patients who achieved the target serum uric acid level with ULORIC 80 mg maintained average serum uric acid levels of < 6 mg/dL throughout treatment.

ULORIC has been studied in more than 4000 patients, in some for more than 5 years. No dose adjustments are required for patients with mild to moderate renal or hepatic impairment.*

Individual results may vary based on factors such as baseline serum uric acid levels. See data for patients with baseline serum uric acid ≥ 10 mg/dL.

*
Mild to moderate renal impairment is defined as serum creatinine levels of > 1.5 mg/dL and ≤ 2 mg/dL or estimated creatinine clearance ≥ 30 mL/min and ≤ 89 mL/min. There are insufficient data in patients with severe renal impairment and no data in patients with severe hepatic impairment. Caution should be exercised in these patients.
Next: Efficacy Data